NASDAQ:CATB - Catabasis Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.91 +0.04 (+4.60 %)
(As of 06/22/2018 04:00 PM ET)
Previous Close$0.91
Today's Range$0.8641 - $0.91
52-Week Range$0.86 - $3.78
Volume1.02 million shs
Average Volume979,909 shs
Market Capitalization$25.26 million
P/E Ratio-0.72
Dividend YieldN/A
Beta0.74
Catabasis Pharmaceuticals logoCatabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics based on safely metabolized and rationally targeted (SMART) linker drug discovery platform in the United States. The company's lead product candidate is Edasalonexent, an oral small molecule, which completed Phase II clinical trial for the treatment of duchenne muscular dystrophy (DMD), as well as Phase I clinical trial for the treatment of additional rare diseases. It is also involved in developing SMART linker conjugates that are in preclinical stage of development, including CAT-5571 for cystic fibrosis (CF) and malfunctioning of CF transmembrane conductance regulator, as well as for the clearance of pathogens, such as P. aeruginosa and B. cenocepacia; and CAT-4001 for the treatment of severe and rare neurodegenerative diseases consisting of Friedreich's ataxia and amyotrophic lateral sclerosis. In addition, the company offers CAT-2000 compounds, which are SMART linker conjugates of nicotinic acid and EPA that are used for the treatment of nonalcoholic steatohepatitis. Catabasis Pharmaceuticals, Inc. has a pre-clinical joint research collaboration agreement with Sarepta Therapeutics, Inc. to explore a combination drug treatment approach for DMD. The company was founded in 2008 and is based in Cambridge, Massachusetts.

Receive CATB News and Ratings via Email

Sign-up to receive the latest news and ratings for CATB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CATB
CUSIPN/A
Phone617-349-1971

Debt

Debt-to-Equity RatioN/A
Current Ratio3.40
Quick Ratio3.40

Price-To-Earnings

Trailing P/E Ratio-0.72
Forward P/E Ratio-0.88
P/E GrowthN/A

Sales & Book Value

Annual Sales$500,000.00
Price / Sales52.83
Cash FlowN/A
Price / CashN/A
Book Value$0.51 per share
Price / Book1.78

Profitability

EPS (Most Recent Fiscal Year)($1.26)
Net Income$-27,360,000.00
Net MarginsN/A
Return on Equity-175.32%
Return on Assets-120.22%

Miscellaneous

Employees36
Outstanding Shares29,030,000

Catabasis Pharmaceuticals (NASDAQ:CATB) Frequently Asked Questions

What is Catabasis Pharmaceuticals' stock symbol?

Catabasis Pharmaceuticals trades on the NASDAQ under the ticker symbol "CATB."

How were Catabasis Pharmaceuticals' earnings last quarter?

Catabasis Pharmaceuticals Inc (NASDAQ:CATB) released its quarterly earnings results on Thursday, May, 10th. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.23) by $0.06. View Catabasis Pharmaceuticals' Earnings History.

When is Catabasis Pharmaceuticals' next earnings date?

Catabasis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Catabasis Pharmaceuticals.

What price target have analysts set for CATB?

6 brokerages have issued 12-month price targets for Catabasis Pharmaceuticals' stock. Their predictions range from $2.00 to $9.00. On average, they expect Catabasis Pharmaceuticals' share price to reach $5.6667 in the next twelve months. View Analyst Ratings for Catabasis Pharmaceuticals.

Who are some of Catabasis Pharmaceuticals' key competitors?

Who are Catabasis Pharmaceuticals' key executives?

Catabasis Pharmaceuticals' management team includes the folowing people:
  • Ms. Jill C. Milne, Co-Founder, CEO, Pres & Director (Age 50)
  • Dr. Andrew J. Nichols, Chief Scientific Officer (Age 57)
  • Dr. Joanne M. Donovan, Chief Medical Officer & Sr. VP of Clinical Devel. (Age 61)
  • Dr. Michael Jirousek Ph.D., Co-Founder and Member of Scientific Advisory Board (Age 59)
  • Ms. Deirdre A. Cunnane, Chief Legal Officer & Treasurer (Age 53)

When did Catabasis Pharmaceuticals IPO?

(CATB) raised $60 million in an initial public offering (IPO) on Thursday, June 25th 2015. The company issued 4,300,000 shares at $13.00-$15.00 per share. Citigroup and Cowen and Company served as the underwriters for the IPO and Oppenheimer and Wedbush PacGrow were co-managers.

Has Catabasis Pharmaceuticals been receiving favorable news coverage?

News coverage about CATB stock has trended positive recently, Accern Sentiment reports. Accern identifies positive and negative media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Catabasis Pharmaceuticals earned a news sentiment score of 0.26 on Accern's scale. They also assigned media stories about the biotechnology company an impact score of 45.72 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Who are Catabasis Pharmaceuticals' major shareholders?

Catabasis Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include CLARUS LIFESCIENCES II, L.P. (6.97%). View Institutional Ownership Trends for Catabasis Pharmaceuticals.

How do I buy shares of Catabasis Pharmaceuticals?

Shares of CATB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Catabasis Pharmaceuticals' stock price today?

One share of CATB stock can currently be purchased for approximately $0.91.

How big of a company is Catabasis Pharmaceuticals?

Catabasis Pharmaceuticals has a market capitalization of $25.26 million and generates $500,000.00 in revenue each year. The biotechnology company earns $-27,360,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis. Catabasis Pharmaceuticals employs 36 workers across the globe.

How can I contact Catabasis Pharmaceuticals?

Catabasis Pharmaceuticals' mailing address is One Kendall SquareBldg. 1400E SuiteB14202, Cambridge MA, 02139. The biotechnology company can be reached via phone at 617-349-1971 or via email at [email protected]


MarketBeat Community Rating for Catabasis Pharmaceuticals (CATB)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  216 (Vote Outperform)
Underperform Votes:  125 (Vote Underperform)
Total Votes:  341
MarketBeat's community ratings are surveys of what our community members think about Catabasis Pharmaceuticals and other stocks. Vote "Outperform" if you believe CATB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CATB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.